FDA approves the first ctDNA-guided adjuvant immunotherapy, for bladder cancer after surgery

Evidence stage: Later-Stage HumanRegulatory status: FDA-approved for the exact stated cancer/useGuideline status: Not addressed

The FDA approved atezolizumab (Tecentriq) and atezolizumab/hyaluronidase-tqjs (Tecentriq Hybreza) as adjuvant treatment for adults with muscle-invasive bladder cancer (MIBC) after cystectomy who have circulating tumor DNA (ctDNA)-based molecular residual disease (MRD), as determined by an FDA-authorized companion diagnostic test (Signatera CDx, approved alongside it) — the first ctDNA-MRD-GUIDED adjuvant immunotherapy approval in oncology, meaning treatment is targeted specifically to patients whose blood tests show detectable cancer DNA after surgery, rather than given to everyone regardless of that result. The approval was based on the randomized, double-blind, placebo-controlled, phase 3 IMvigor011 trial (ClinicalTrials.gov NCT04660344; primary publication in the New England Journal of Medicine, DOI 10.1056/NEJMoa2511885, PMID 41124204), which enrolled 250 patients with MIBC who had ctDNA MRD detected by serial blood testing within 12 months of cystectomy. Atezolizumab reduced the risk of disease recurrence or death by 36% and the risk of death by 41% compared with placebo in this ctDNA-positive population — a real, disclosed, biomarker-selected benefit.

What This Means

In the randomized, phase 3 IMvigor011 trial, atezolizumab reduced the risk of disease recurrence or death by 36% and the risk of death by 41% compared with placebo, specifically in muscle-invasive bladder cancer patients whose blood tests showed detectable circulating tumor DNA (ctDNA) after surgery -- supporting the first FDA approval of a ctDNA-MRD-GUIDED adjuvant immunotherapy in oncology, meaning the drug is targeted to patients most likely to benefit rather than given to everyone regardless of this blood test result.

What This Doesn't Mean

This approval is specifically for the ctDNA-POSITIVE population -- patients who test ctDNA-negative after cystectomy were shown in the same trial program to have low recurrence risk without additional treatment, and this record makes no claim that atezolizumab benefits ctDNA-negative patients, who are not the population this approval covers.

Why It Matters

A real, biomarker-selected adjuvant immunotherapy approval -- using a blood test to decide WHO gets treatment, not just WHAT treatment to give -- is a genuinely new paradigm in bladder cancer care and precision oncology broadly, adding real depth to this site's "biomarkers" topic area and to its bladder cancer coverage.

Promise & Proof

Proof — strength of the evidence 5 / 5
  • Base score from evidence stage: Later-Stage Human.
  • FDA-approved for the exact stated cancer/use.
Promise — potential significance if later evidence holds up 3 / 5
  • Baseline — a validly-evidenced story starts here; every further point below is an explicit, checkable reason.
  • The record includes substantive editorial reasoning about why this discovery matters.
  • A distinct follow-on/confirmatory study or trial is already cited as a secondary source — the field is already building on this finding.

These two ratings are automatically computed from this story's own structured evidence fields and are shown separately on purpose — they are never combined into one score. They describe this record, not a medical recommendation: they do not establish medical certainty, do not substitute for reading the cited sources, and are recalculated whenever the underlying evidence changes.

Population / Applicability

Studied in: Adults with muscle-invasive bladder cancer (MIBC) who had radical cystectomy with lymph node dissection and had detectable circulating tumor DNA (ctDNA) molecular residual disease (MRD) on serial blood testing within 12 months of surgery, randomized to atezolizumab or placebo, in the randomized, double-blind, phase 3 IMvigor011 trial. (Adults)

Requires ctDNA MRD testing via an FDA-authorized companion diagnostic (Signatera CDx) after cystectomy -- not appropriate for patients who have not had this specific testing. This record has not independently reviewed the full safety/tolerability profile, which should be added before publication.

Full evidence details
Study design
Randomized controlled trial
Sample size
250

Funding & Conflicts

Sponsor/developer: Genentech, Inc. (a member of the Roche Group) -- not independently confirmed against a primary corporate-disclosure document.

Regulatory status by jurisdiction

United States (FDA)

Status
FDA-approved for the exact stated cancer/use
Indication
Adults with muscle-invasive bladder cancer after cystectomy who have ctDNA molecular residual disease, as determined by an FDA-authorized test.
Biomarker requirement
Circulating tumor DNA (ctDNA) molecular residual disease, as determined by Signatera CDx
Decision date
2026-05-15
Source
Regulator record (opens in a new tab)

Guideline positions

Guideline

Position
Not addressed
Last verified
2026-08-13

Primary evidence supporting this story

Additional context

Why Should I Trust This?

  • 1 source at Tier 2 — Peer-reviewed primary research, trial registries, regulatory documents, official conference abstracts
  • Last reviewed: 2026-08-13

This panel summarizes real, checkable facts about this record's own sources and review status — it is not a trust score, and reading it is not a substitute for reading the cited sources yourself.

Discovery Timeline

Every recorded change to this record's content or publication status, in order.

  1. Status change — Status changed from "Legacy / Unverified" to "In editorial review".
  2. Status change — Status changed from "In editorial review" to "Verified".

Last reviewed

Related discoveries

FDA approves the first ctDNA-guided adjuvant immunotherapy, for bladder cancer after surgery

https://cancerdiscoveries.com/discoveries/fda-approves-the-first-ctdna-guided-adjuvant-immunotherapy-for-bladder-cancer-after-surgery/

Evidence stage: Later-Stage Human

What This Means

In the randomized, phase 3 IMvigor011 trial, atezolizumab reduced the risk of disease recurrence or death by 36% and the risk of death by 41% compared with placebo, specifically in muscle-invasive bladder cancer patients whose blood tests showed detectable circulating tumor DNA (ctDNA) after surgery -- supporting the first FDA approval of a ctDNA-MRD-GUIDED adjuvant immunotherapy in oncology, meaning the drug is targeted to patients most likely to benefit rather than given to everyone regardless of this blood test result.

What This Doesn't Mean

This approval is specifically for the ctDNA-POSITIVE population -- patients who test ctDNA-negative after cystectomy were shown in the same trial program to have low recurrence risk without additional treatment, and this record makes no claim that atezolizumab benefits ctDNA-negative patients, who are not the population this approval covers.

Why It Matters

A real, biomarker-selected adjuvant immunotherapy approval -- using a blood test to decide WHO gets treatment, not just WHAT treatment to give -- is a genuinely new paradigm in bladder cancer care and precision oncology broadly, adding real depth to this site's "biomarkers" topic area and to its bladder cancer coverage.

Primary sources

  • Adjuvant Atezolizumab Guided by Circulating Tumor DNA in Muscle-Invasive Bladder Cancer (New England Journal of Medicine) — https://doi.org/10.1056/NEJMoa2511885 (DOI 10.1056/NEJMoa2511885, PMID 41124204)

Date verified: 2026-08-13

Correction status: No correction or retraction